Very exciting to have Judo Bio scientist Jeremy Cunniff present our data at #ots24 demonstrating delivery of our ligand-siRNA conjugates (megalin-STRIKERs) to the kidney to silence the production of target mRNA. #siRNAtotheKidney
Judo Bio
Biotechnology Research
Cambridge, MA 1,276 followers
Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic and renal diseases.
About us
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.
- Website
-
https://judo.bio/
External link for Judo Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
Cambridge, MA 02139, US
Employees at Judo Bio
Updates
-
We’re excited to launch Judo Bio to the world. Genetic Engineering & Biotechnology News explores our innovative approach to delivering siRNA to the kidney. #siRNAtotheKidney https://lnkd.in/ebgi9hee
-
We're presenting preclinical data showing the use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to the kidney, silencing the production of target mRNA. We’re in Montreal at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society. #ots24 #oligomeeting #siRNAtotheKidney https://lnkd.in/e2zSp_Pd
-
-
Judo Bio welcomes Dr. Rajiv Patni as CEO, a 25-year biopharma veteran with a stellar track record for leading company growth and advancing transformative medicines, including drug approvals, indication expansions, BD deals and M&A. #siRNAtotheKidney https://lnkd.in/giEF8tnM
-
-
Judo Bio launches with $100 million in combined seed and Series A financing from leading investors to advance an initial pipeline designed to silence mRNA in the proximal tubule epithelial cells of the kidney. #siRNAtotheKidney https://lnkd.in/giEF8tnM
-
-
Introducing Judo Bio, launching with our STRIKE platform to create oligonucleotide medicines delivered to the kidney. We have discovered a way to overcome challenges of reaching the kidney with oligonucleotide medicines, opening a new path for treating systemic & renal diseases. #siRNAtotheKidney https://judo.bio/